Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul-Sep;39(3):249-251.
doi: 10.4103/iju.iju_103_23. Epub 2023 Jun 30.

Re: Kumar A, Yadav S, Krishnappa RS, Gautam G, Raghavan N, Bakshi G, et al. The Urological Society of India guidelines for the evaluation and management of prostate cancer (executive summary). Indian J Urol 2022;38:252-7

Shyam Singh Bisht  1 , Deepak Gupta  2 , Susovan Banerjee  1 , Tejinder Kataria  1
Affiliations

Re: Kumar A, Yadav S, Krishnappa RS, Gautam G, Raghavan N, Bakshi G, et al. The Urological Society of India guidelines for the evaluation and management of prostate cancer (executive summary). Indian J Urol 2022;38:252-7

Shyam Singh Bisht et al. Indian J Urol. 2023 Jul-Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: There are no conflicts of interest.

References

    1. Kumar A, Yadav S, Krishnappa RS, Gautam G, Raghavan N, Bakshi G, et al. The Urological Society of India guidelines for the evaluation and management of prostate cancer (executive summary) Indian J Urol. 2022;38:252–7. - PubMed
    1. Pasalic D, Kuban DA, Allen PK, Tang C, Mesko SM, Grant SR, et al. Dose escalation for prostate adenocarcinoma: A long-term update on the outcomes of a phase 3, single institution randomized clinical trial. Int J Radiat Oncol Biol Phys. 2019;104:790–7. - PMC - PubMed
    1. Michalski JM, Moughan J, Purdy J, Bosch W, Bruner DW, Bahary JP, et al. Effect of standard versus dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: The NRG oncology RTOG 0126 randomized clinical trial. JAMA Oncol. 2018;4:e180039. - PMC - PubMed
    1. Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24:1990–6. - PubMed
    1. Xu N, Rossi PJ, Jani AB. Toxicity analysis of dose escalation from 75.6 gy to 81.0 gy in prostate cancer. Am J Clin Oncol. 2011;34:11–5. - PubMed